Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep;68(9):1899-1907.
doi: 10.1007/s00125-025-06446-y. Epub 2025 Aug 4.

Insulin DEgludec/LIraglutide versus multiple daily insulin injections in the transition from hospital to outpatient management assessed by continuous glucose monitoring: the DELI transition trial

Ana M Gómez-Medina  1 , Diana C Henao-Carillo  2 , Lina P Villamil-Castañeda  2 , Yaline Gómez-Quesada  2 , Oscar M Muñoz-Velandia  3 , Carlos A Yepes  2 , Salma N Chaim  4 , Carlos E Pertuz-Noriega  4 , Pablo Aschner  4
Affiliations

Insulin DEgludec/LIraglutide versus multiple daily insulin injections in the transition from hospital to outpatient management assessed by continuous glucose monitoring: the DELI transition trial

Ana M Gómez-Medina et al. Diabetologia. 2025 Sep.

Abstract

Aims/objective: The aim of the study was to assess the safety profile (defined as the percentage of patients with at least one hypoglycaemic event [more than 15 min with glucose levels <3.0 mmol/l as documented by continuous glucose monitoring] in the first 4 weeks of follow-up) for insulin degludec/liraglutide (IDegLira) compared with multiple daily insulin injections (MDI) during the transition from hospital to an outpatient setting.

Methods: The study was an open-label, randomised, controlled clinical trial comparing IDegLira to MDI after hospital discharge in patients with type 2 diabetes. The study evaluated the percentage of patients with at least one hypoglycaemic event, the hypoglycaemia event density, the time in range (TIR 3.8-10 mmol/l), the time below range (TBR <3.0 or <3.8 mmol/l), and other glycaemic management metrics measured by continuous glucose monitoring.

Results: Sixty-four patients were included in the analysis (32 in each group). They had a baseline HbA1c of 103 ± 11.6 mmol/mol (11.6 ± 1.7%) and age of 58 ± 12.4 years (means ± SD). The proportion of patients with at least one hypoglycaemic event (plasma glucose <3.0 mmol/l) was lower in the IDegLira group than in the MDI group (6.2% vs 31.3%; p<0.010), as was the hypoglycaemia event density (incidence rate ratio 15.2; 95% CI 6.2, 48.2; p<0.001), TBR <3.8 mmol/l (0.9% vs 2.9%; p=0.019) and TBR <3.0 mmol/l (0.6% vs 1.3%, p=0.008). The TIR 3.8-10 mmol/l was higher in the IDegLira group (80.6% vs 69.7%; p=0.008). The findings were consistent regardless of baseline HbA1c.

Conclusions/interpretation: IDegLira proved to be safer and more effective than MDI for individuals with type 2 diabetes who had suboptimal glycaemic control, aiding in their transition from hospital to outpatient care.

Trial registration: Clinicaltrials.gov NCT05767255 FUNDING: This research was funded by a grant from the Asociación Colombiana de Endocrinología, Diabetes y Metabolismo (ACE).

Keywords: Colombia; Hospital to home transition; IDegLira; Type 2 diabetes mellitus.

PubMed Disclaimer

Conflict of interest statement

Acknowledgements: Medical writing in English and editorial assistance were provided by Festina Lente (Medellin, Colombia) and funded by Novo Nordisk Colombia. The collaboration agreement between the Pontificia Universidad Javeriana and Springer Nature enabled the open access publication. The authors assume full responsibility for the content and conclusions expressed in this manuscript. Novo Nordisk did not influence the content of this publication nor participate in the study design, data collection, analysis, interpretation or review, or in any stage of the publication process. Data availability: The datasets generated or analysed for the current study are available upon reasonable request from the sponsor institution (Hospital Universitario San Ignacio). Funding: Open Access funding provided by Colombia Consortium. This research was funded by a grant from the Asociación Colombiana de Endocrinología, Diabetes y Metabolismo (ACE). Authors’ relationships and activities: AMG-M received speaker fees from Novo Nordisk, Astra Zeneca, Sanofi, Eli Lilly, Boehringer Ingelheim, Abbott and Medtronic. DCH-C received speaker fees from Novo Nordisk, Sanofi and Abbott. The remaining authors declare that there are no relationships or activities that might bias, or be perceived to bias, their work. Contribution statement: AMG-M conceived the study. AMG-M, DCH-C, LPV-C, OMM-V, CAY, YG-Q and PA designed the study, analysed the data and critically reviewed the protocol. SNC and CEP-N participated in the acquisition of data and database elaboration. All authors contributed to the final version of the manuscript, and approved the version to be published. AMG-M is the guarantor of this work, and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Figures

Fig. 1
Fig. 1
Flow chart for participant inclusion. aFor the patients who were lost to follow-up at 28 days, the information available from the first 14 days was taken into account
Fig. 2
Fig. 2
Glucose metrics obtained through CGM
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Pasquel FJ, Urrutia MA, Cardona S et al (2021) Liraglutide hospital discharge trial: a randomized controlled trial comparing the safety and efficacy of liraglutide versus insulin glargine for the management of patients with type 2 diabetes after hospital discharge. Diabetes Obes Metab 23(6):1351–1360. 10.1111/dom.14347 - PMC - PubMed
    1. Donihi AC (2017) Practical recommendations for transitioning patients with type 2 diabetes from hospital to home. Curr Diab Rep 17(7):52. 10.1007/s11892-017-0876-1 - PubMed
    1. Galindo RJ, Moazzami B, Scioscia MF et al (2023) A randomized controlled trial comparing the efficacy and safety of IDegLira versus basal-bolus in patients with poorly controlled type 2 diabetes and very high HbA1c ≥9–15%: DUAL HIGH trial. Diabetes Care 46(9):1640–1645. 10.2337/dc22-2426 - PMC - PubMed
    1. Vargas-Uricoechea H, Frias JP, Vargas-Sierra HD (2023) Fixed-ratio combinations (basal insulin plus GLP-1RA) in type 2 diabetes. An analytical review of pivotal clinical trials. Rev Diabet Stud 19(1):14–27. 10.1900/RDS.2023.19.14 - PMC - PubMed
    1. Lingvay I, Pérez Manghi F, García-Hernández P et al (2016) Effect of insulin glargine up-titration vs insulin degludec/liraglutide on glycated hemoglobin levels in patients with uncontrolled type 2 diabetes: the DUAL V randomized clinical trial. JAMA 315(9):898–907. 10.1001/jama.2016.1252 - PubMed

Associated data

LinkOut - more resources